ILMN - Illumina, Inc.

Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026

SAN DIEGO, Oct. 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the third quarter 2026 following the close of market on Thursday, October 29, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Oct 08, 2026 12:06 PM • prnewswire.com

Illumina releases SpliceAI2 to help advance rare disease research

In a rare disease research dataset, SpliceAI2 identified 17% more disease-relevant variants compared to other splicing models Illumina's genomic AI models now collectively enable researchers to identify 2x as many variants with predicted biological impact SAN DIEGO, Oct. 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today introduced SpliceAI2, a new genomic AI model designed to address one of the central challenges in genomics: understanding the functional consequences of genetic variation. SpliceAI2 helps researchers identify disease-relevant splice variants that otherwise may go unnoticed.

Oct 08, 2026 05:15 AM • prnewswire.com

Illumina, Inc. (NASDAQ:ILMN) Stock Now Rated “Hold” by Sell-Side Analysts

Illumina, Inc. (NASDAQ: ILMN - Get Free Report) has earned a consensus rating of "Hold" from the eighteen brokerages that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and ten have assigned a buy recommendation to the company. The

Oct 06, 2026 10:46 PM • defenseworld.net

Argent Capital Management LLC Purchases New Holdings in Illumina, Inc. $ILMN

Argent Capital Management LLC purchased a new position in shares of Illumina, Inc. (NASDAQ: ILMN) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 14,634 shares of the life sciences company's stock, valued at approximately $4,005,000. Other hedge funds also

Oct 05, 2026 09:07 AM • defenseworld.net

Illumina (NASDAQ:ILMN) Reaches New 52-Week High – What’s Next?

Illumina, Inc. (NASDAQ: ILMN - Get Free Report) shares hit a new 52-week high on Tuesday. The company traded as high as $278.99 and last traded at $273.1990, with a volume of 227282 shares trading hands. The stock had previously closed at $271.90. Analyst Upgrades and Downgrades A number of analysts have recently commented on the

Oct 01, 2026 01:41 AM • defenseworld.net

The Top HealthTech Questions Landing on Our Desks

Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled this guide to answer a mix of the most frequent and most interesting questions we have received regarding our Healthcare Technology and Innovation Index (HTEC).

Sep 30, 2026 03:06 AM • etftrends.com

Where Will Illumina Stock Be in 5 Years If Its AI Bet Pays Off?

Illumina (ILMN +0.04%) is building a deeper AI strategy around the biological data created by its sequencing technology. The Billion Cell Atlas, expanding drugmaker partnerships, and improving core business could create a new growth engine if Illumina can turn its scientific advantage into recurring commercial revenue.

Sep 29, 2026 04:45 PM • fool.com

REGN or ILMN: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Regeneron (REGN) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?

Sep 29, 2026 08:41 AM • zacks.com

Is the Options Market Predicting a Spike in Illumina Stock?

Investors need to pay close attention to ILMN stock based on the movements in the options market lately.

Sep 28, 2026 10:05 AM • zacks.com

Illumina (NASDAQ:ILMN) Reaches New 52-Week High – Here’s Why

Illumina, Inc. (NASDAQ: ILMN - Get Free Report) shares reached a new 52-week high during mid-day trading on Wednesday. The company traded as high as $254.85 and last traded at $252.2590, with a volume of 189250 shares changing hands. The stock had previously closed at $247.46. Analyst Upgrades and Downgrades ILMN has been the topic of

Sep 25, 2026 12:21 AM • defenseworld.net

Illumina Stock Surges 94.9% YTD: What's Behind the Rally?

ILMN's 94.9% YTD rally reflects strong sequencing growth, clinical adoption and a raised 2026 outlook despite China headwinds.

Sep 24, 2026 07:45 AM • zacks.com

3 Analysts, 3 Trades to Make Today

Louis says buy the AI dip

Sep 22, 2026 01:00 PM • investorplace.com

Illumina (ILMN) is a Top-Ranked Momentum Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Sep 11, 2026 06:50 AM • zacks.com

Baird Financial Group Inc. Decreases Position in Illumina, Inc. $ILMN

Baird Financial Group Inc. lowered its stake in Illumina, Inc. (NASDAQ: ILMN) by 14.6% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 182,425 shares of the life sciences company's stock after selling 31,094 shares during the quarter. Baird Financial Group Inc. owned 0.12% of Illumina

Sep 10, 2026 11:57 PM • defenseworld.net

This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Sep 09, 2026 08:40 AM • benzinga.com

3 Stocks Soon Joining the S&P 500

The S&P 500 is set for another shakeup, with Bloom Energy (BE), Everpure (P), and Illumina (ILMN) all joining in the next quarterly rebalancing near the end of September.

Sep 08, 2026 05:40 PM • zacks.com

3 Promising Genomics Stocks in the Spotlight in 2026

Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.

Sep 08, 2026 09:50 AM • zacks.com

Illumina (ILMN) Upgraded to Buy: What Does It Mean for the Stock?

Illumina (ILMN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sep 07, 2026 09:01 AM • zacks.com

Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

NEW YORK, Sept. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 21, 2026, to coincide with the quarterly rebalance.

Sep 04, 2026 03:15 PM • prnewswire.com

Bloom Energy, Illumina, Everpure Rise On S&P 500 Inclusion

AI energy play Bloom Energy will be added to the S&P 500 index on Sept. 21. Illumina and Everpure also will join.

Sep 04, 2026 02:39 PM • investors.com

Illumina price target raised to $200 from $160 at Barclays

$200.00 (was $273.54)

Barclays

Oct 07, 2026 05:49 AM • TheFly

Illumina price target raised to $305 from $226 at Guggenheim

$305.00 (was $270.81)

Subbu Nambi · Guggenheim

Oct 01, 2026 08:27 AM • TheFly

Illumina price target raised to $300 from $220 at Leerink

$300.00 (was $273.63)

Leerink Partners

Sep 29, 2026 08:48 AM • TheFly

Illumina price target raised to $305 from $225 at Piper Sandler

$305.00 (was $270.00)

David Westenberg · Piper Sandler

Sep 28, 2026 06:46 AM • TheFly

Illumina assumed with a Buy at UBS

$260.00 (was $211.06)

UBS

Sep 09, 2026 07:17 AM • TheFly

Illumina price target raised to $235 from $180 at Argus

$235.00 (was $213.25)

Argus Research

Sep 03, 2026 07:48 AM • TheFly

Illumina price target raised to $205 from $190 at Canaccord

$205.00 (was $205.10)

Canaccord Genuity

Aug 03, 2026 07:06 AM • TheFly

Illumina price target raised to $230 from $170 at RBC Capital

$230.00 (was $199.13)

RBC Capital

Jul 31, 2026 10:09 AM • TheFly

Illumina price target raised to $215 from $185 at Bernstein

$215.00 (was $205.09)

Bernstein

Jul 31, 2026 07:50 AM • TheFly

Illumina price target raised to $226 from $200 at Guggenheim

$226.00 (was $205.09)

Guggenheim

Jul 31, 2026 06:52 AM • TheFly

Illumina price target raised to $160 from $145 at Barclays

$160.00 (was $205.09)

Barclays

Jul 31, 2026 05:09 AM • TheFly

Illumina price target raised to $210 from $175 at Leerink

$210.00 (was $186.89)

Puneet Souda · Leerink Partners

Jul 17, 2026 08:45 AM • TheFly

Illumina price target raised to $190 from $140 at Canaccord

$190.00 (was $190.05)

Kyle Mikson · Canaccord Genuity

Jul 14, 2026 06:51 AM • TheFly

Illumina price target raised to $200 from $180 at Guggenheim

$200.00 (was $176.55)

Guggenheim

Jun 29, 2026 07:00 AM • TheFly

Illumina resumed with a Market Perform at Bernstein

$185.00 (was $177.65)

Bernstein

Jun 26, 2026 06:27 AM • TheFly

Illumina price target raised to $180 from $170 at Guggenheim

$180.00 (was $162.96)

Guggenheim

Jun 01, 2026 07:27 AM • TheFly

Illumina resumed with an Outperform at RBC Capital

$170.00 (was $143.24)

RBC Capital

May 14, 2026 04:23 PM • TheFly

Illumina upgraded to Outperform from Neutral at Daiwa

$155.00 (was $145.00)

Illumina to Outperform · Daiwa

May 14, 2026 05:05 AM • TheFly

Illumina price target lowered to $140 from $150 at Canaccord

$140.00 (was $126.74)

Canaccord Genuity

May 01, 2026 06:41 AM • TheFly

Illumina price target raised to $122 from $110 at Barclays

$122.00 (was $126.74)

Barclays

May 01, 2026 05:28 AM • TheFly